The cancer care continuum is shifting, and pharma can help

Posted by Sankalp Sethi on Jun 5, 2020 8:00:00 AM

Kavit Patel, Kyle Harpole and Gustavo Poblete co-wrote this blog with Sankalp Sethi. 

Access COVID-19 resources

COVID-19 is posing a threat to the community oncology business model, but it’s also creating a case for the practices to play an elevated role in the oncology care continuum. While hospitals focus on managing patients with COVID-19, community oncology practices have become the safer zone for cancer patients to continue their careoften closer to home and at a lower cost. These themes were front and center at the 2020 Community Oncology Conference, held virtually by Community Oncology Alliance (COA) in April. Following the event, we gathered the perspectives of two community oncology leaders: Jeffrey Patton, MD, CEO at OneOncology and executive chairman of the board at Tennessee Oncology, and Jeffrey Vacirca, MD, FACP, CEO and managing partner at New York Cancer & Blood Specialists and board member at OneOncology. As markets begin to reopen and new COVID-19 hot spots potentially emerge, we need to consider how community oncology practices have been affected and determine how manufacturers can adjust their approach to support cancer patients and oncologists moving forward.


>
Read More

Oncology practices look a lot different than they did eight weeks ago

Posted by David Kriesman on May 4, 2020 1:00:52 PM

Prashant Poddar co-wrote this blog post with David Kriesman.

Oncologists are precisionists, relying on every tool at their disposal and a well-connected network of practitioners to make the best choices for their patients. But that approach is nearly impossible during the COVID-19 crisis which is disproportionately affecting cancer care. Oncologists are struggling with a newfound loss of control over the consistency of their business and lack the confidence they once had to make optimal treatment decisions and keep their patients safe.


>
Read More

Four drug distribution and support program considerations for oncology manufacturers

Posted by Nakul Korde on Apr 10, 2020 10:19:45 AM

Anshul Agarwal co-wrote this blog post with Nakul Korde.

Access COVID-19 resources

Amid the growing concerns and uncertainty of COVID-19, the CDC has issued guidance for individuals to stockpile several weeks of medications and supplies. However, this is easier said than done, especially for oncology and specialty medications as many of them have stringent administrative, accessibility and logistical barriers. Given the global spread and impact of COVID-19, supply chain disruptions for these drugs cannot be ruled out. In such situations, it’s natural for patients to be concerned about getting their prescriptions filled on time and with minimal hassles and exposure.


>
Read More

Pharma Can Meet Cancer Patients’ and Oncologists’ Unique COVID-19 Needs

Posted by Jon Roffman on Mar 25, 2020 10:30:20 AM

Prashant Poddar co-wrote this blog post with Jon Roffman.

Access COVID-19 resources

As the SARS-CoV-2 pandemic rages on, questions remain about how the virus is transmitted between people, how quickly it spreads and how contagious it is. But one thing is certain: The elderly and immunosuppressed patient populations, including those with cancer, are among the most at risk.

These patients need oncology manufacturers, healthcare providers and other stakeholders to ensure that they have continued access to care while minimizing exposure to the virus. Together, we can play a critical role in helping to improve and extend the lives of oncology patients. This should be our central focus today, knowing that it likely will change the way that we approach tomorrow and beyond.


>
Read More